10-Q: Precision Optics Sees Revenue Surge, Margin Pressure

Precision Optics Corporation reported a significant 59.2% revenue increase for Q1 2026, driven by Systems Manufacturing, despite a sharp decline in gross margin and a wider net loss.

Summary

• Total revenues for the quarter ended September 30, 2025, increased by $2,483,770, or 59.2%, to $6,680,823 compared to $4,197,053 in the prior year period.
• Systems Manufacturing revenue surged by nearly 300%, or $3,641,528, reaching $4,866,706, primarily due to increased customer demand and scaling of manufacturing capabilities.
• Gross profit decreased by $170,972 to $946,358, and gross margin significantly declined to 14.2% from 26.6% in the prior year.
• Net loss widened to $(1,637,030) from $(1,311,247) in the same period last year.
• Operating loss increased to $(1,595,255) from $(1,246,941) year-over-year.
• Net cash provided by operating activities improved to $78,227, compared to $318,622 net cash used in operating activities in the prior year.
• The company did not meet its minimum annual debt service coverage ratio covenant of 1.2x for the fiscal year ended June 30, 2024, and again for September 30, 2025, but received waivers from its lender.
• A non-statutory stock option inducement grant of 60,000 shares was awarded to Joseph Traut, effective October 1, 2025, with an exercise price of $4.34 per share, vesting over three years.

Sentiment

Score: 4

Explanation: While revenue growth is strong, the significant decline in gross margin, widening net loss, and ongoing debt covenant non-compliance indicate underlying operational and financial challenges. The improvement in operating cash flow and strategic talent acquisition are positive, but overshadowed by profitability concerns and the need for potential future financing.

Positives

• Total revenues increased by 59.2% to $6,680,823, demonstrating strong top-line growth.
• Systems Manufacturing revenue nearly tripled, growing by 297.3%, driven by significant customer demand and expanded manufacturing capabilities.
• Net cash provided by operating activities improved significantly, moving from a net cash outflow of $318,622 in the prior year to a net cash inflow of $78,227.
• Ross Optical Industries revenue increased by 13.7%, attributed to customers no longer postponing deliveries.
• The company successfully completed an equity raise of at least $4,500,000 by February 21, 2025, satisfying a condition for a debt covenant waiver.
• The grant of 60,000 stock options to Joseph Traut as an inducement suggests the attraction of key talent to the company.

Negatives

• Gross margin significantly decreased to 14.2% from 26.6% in the prior year, indicating pressure on profitability.
• Gross profit declined by 15.3% despite substantial revenue growth.
• Net loss widened to $(1,637,030) from $(1,311,247) in the comparable period.
• Operating loss increased to $(1,595,255) from $(1,246,941).
• Engineering Design Services revenue decreased by 59.3% due to program transfers and completion of prior engagements.
• MicroOptics Lab revenue decreased by 76.5% due to delays in receiving new production orders from a defense customer.
• Selling, General and Administrative (SG&A) expenses increased by 13.6% due to higher stock compensation, severance, and consulting expenses.
• Total stockholders' equity decreased from $12,258,834 at June 30, 2025, to $10,923,443 at September 30, 2025.

Risks

• The company did not meet its minimum annual debt service coverage ratio covenant of 1.2x for the fiscal year ended June 30, 2024, and again as of September 30, 2025, requiring waivers from its lender.
• Future advances under the revolving line of credit are contingent on achieving a minimum Debt Service Coverage ratio of 1.20x based on quarterly testing, which was not met as of September 30, 2025.
• Lower utilization of engineering resources for customer-paid engineering contributes to decreased gross profit.
• Low yields for manufacturing lines producing single-use medical devices negatively impact gross profit.
• Delays in receiving new production orders from defense customers for the MicroOptics Lab segment pose a risk to revenue and profitability.
• Delayed revenue opportunities within the product development pipeline could further impact Engineering Design Services revenue.
• Management believes cash on hand and cash generated solely from operations may be insufficient to meet working capital needs for the next 12 months, potentially requiring external financing in the short-term.
• The company is subject to general risks outlined in its Annual Report on Form 10-K, which have not materially changed.

Future Outlook

Management believes that the company's available cash and cash equivalents, cash generated from operations, the eventual availability of its line of credit, and its ability to raise funds in the capital markets will be sufficient to meet working capital and capital expenditure requirements for at least 12 months from the filing date. However, management also notes that cash on hand and cash generated solely from operations may be insufficient, potentially requiring external financing in the short-term.

Management Comments

• Revenue decreases in the engineering category resulted from decreased demand for services, primarily from the transfer of our single-use cystoscope program from Engineering Design Services to Systems Manufacturing.
• Engineering revenue was lower due to the completion of product development engagements in the prior year and delayed revenue opportunities within the product development pipeline for the current quarter.
• Systems Manufacturing revenue increased nearly 300% due primarily to significant increases in customer demand and the resultant scaling of manufacturing capabilities.
• MicroOptics Lab revenue decreased primarily due to delays in receiving new production orders from our defense customer.
• The increase in Ross Optical Industries revenue is attributable to the inability of our customers to continue to postpone deliveries that had previously been delayed due to the introduction of new tariffs and the resultant uncertainty.
• The primary factors for the decrease in gross profit include lower utilization of engineering resources for customer-paid engineering, low yields for manufacturing lines producing single-use medical devices, and delays in the reorder for the MicroOptics Lab.
• The increase in SG&A for the three-month period was primarily due to increased stock compensation, severance, and consulting expenses.

Industry Context

Precision Optics operates in the medical devices and advanced defense/aerospace product segments, which are characterized by high demand for specialized optical instruments and imaging systems. The shift of the single-use cystoscope program from engineering to manufacturing reflects a potential maturation of product development into commercial production, aligning with the industry trend towards smaller, disposable, and enhanced imaging systems for minimally invasive surgery. Delays in defense orders for MicroOptics Lab suggest potential volatility in government contracting cycles, while the increase in Ross Optical revenue due to tariff-related delivery postponements highlights the impact of global trade policies on supply chains in the optical components sector. The company's expansion into new facilities in Maine and Massachusetts indicates a strategic investment in scaling operations to meet anticipated demand in these specialized markets.

Comparison to Industry Standards

• The significant revenue growth in Systems Manufacturing (nearly 300%) suggests strong market penetration or increased demand for outsourced high-complexity optical manufacturing, potentially outperforming general industry growth rates for specialized optical components and systems.
• The sharp decline in gross margin from 26.6% to 14.2% is a concern, especially when compared to industry benchmarks for precision manufacturing or medical device components, which often aim for higher margins due to specialized expertise and intellectual property. This could indicate pricing pressure, increased production costs, or inefficiencies (e.g., low yields for single-use medical devices) that are below best-in-class operational standards.
• The company's repeated non-compliance with debt service coverage ratio covenants, even with waivers, suggests a higher financial risk profile compared to more stable industry peers who consistently meet such obligations.
• The investment in new operating leases in South Portland, Maine, and Littleton, Massachusetts, indicates a commitment to expanding manufacturing and R&D footprint, a common strategy among growing companies in high-tech sectors, but the associated liabilities need to be managed carefully against profitability.

Management Changes

Legal Proceedings

• The company may be involved in legal matters arising in the ordinary course of business, which management believes are currently insignificant. However, such matters could have a material adverse effect on the business.

Stakeholder Impact

• **Shareholders**: Experience a wider net loss and a decrease in total stockholders' equity, potentially impacting share value. The stock option grant to Joseph Traut could dilute existing shares upon exercise.
• **Employees**: Increased stock compensation is noted in SG&A, and severance expenses indicate some workforce adjustments. The hiring of Joseph Traut suggests investment in key personnel.
• **Customers**: Benefit from scaled manufacturing capabilities in Systems Manufacturing, but may face delays in MicroOptics Lab orders. The transfer of the single-use cystoscope program to manufacturing could mean more readily available products.
• **Lenders (Main Street Bank)**: The company's repeated non-compliance with debt covenants creates ongoing risk, though waivers have been granted. Future advances are contingent on meeting financial ratios.
• **Suppliers**: Increased manufacturing activity in Systems Manufacturing likely translates to higher demand for raw materials and components.

Next Steps

• Continue to scale Systems Manufacturing capabilities to meet increased customer demand.
• Address issues leading to low yields in single-use medical device manufacturing lines to improve gross margins.
• Work to secure new production orders for the MicroOptics Lab from defense customers to reverse revenue decline.
• Monitor and manage the debt service coverage ratio to ensure compliance for future credit availability.
• Potentially seek external financing in the short-term if cash from operations proves insufficient for working capital needs.

Key Dates

Recommendation

Precision Optics Corporation presents a mixed financial picture. While the substantial revenue growth, particularly in Systems Manufacturing, and the improvement in operating cash flow are positive indicators of market demand and operational efficiency gains, these are significantly offset by a sharp decline in gross margin and a widening net loss. The company's recurring non-compliance with debt covenants, even with waivers, signals underlying financial fragility and potential future liquidity challenges, despite a recent equity raise. The strategic expansion through new leases and the attraction of key talent are long-term positives, but the immediate profitability pressures and operational inefficiencies (low yields, delayed orders) warrant caution. Given the strong top-line growth but persistent profitability and debt concerns, a 'hold' recommendation is appropriate. Investors should monitor gross margin recovery, sustained operating cash flow, and compliance with debt covenants before considering further investment.

Keywords

Precision Optics, POCI, SEC Filing, 10-Q, Quarterly Report, Financial Results, Revenue Growth, Gross Margin, Net Loss, Systems Manufacturing, Medical Devices, Defense/Aerospace, Stock Options, Debt Covenants, Operating Cash Flow, Micro-optics, Ross Optical